The Institute for Clinical and Economic Review (ICER) issued a final evidence report,1 including a systematic literature review and cost-benefit analyses, to support a July 20, 2017, public meeting of the New England Comparative Effectiveness Public Advisory Council on abuse-deterrent (AD) opioids. We summarize key findings of the report and provide our independent assessment of their implications for health policy. While acknowledging the importance of reducing stigma in clinical discourse, we use the term abuse for consistency with the report nomenclature.